Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Trial of AAVAnc80-antiVEGF Gene Therapy in Individuals With Unilateral Vestibular Schwannoma

NCT06517888 is registered in ClinicalTrials.gov with Akouos, Inc. as lead sponsor.

NCT NCT06517888
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06517888 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Trial of AAVAnc80-antiVEGF Gene Therapy in Individuals With Unilateral Vestibular Schwannoma
Lead sponsor
Akouos, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 17, 2025
Completion date
August 31, 2029
Enrollment
27 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

vestibular schwannoma